Today the Health Resources and Services Administration (HRSA) officially requested White House Office of Management and Budget (OMB) review of new "omnibus guidelines" on the 340B drug discount program. While the guidelines are not yet available to the public, the document will presumably fulfill HRSA's pledge last year to address "key policy issues raised by various stakeholders committed to the integrity of the 340B program." This latest action follows HRSA's request last month for OMB clearance of its proposed rule implementing 340B program enforcement authorities and pricing policies under the Affordable Care Act; that rule is still pending at OMB.
This article is presented for informational purposes only and is not intended to constitute legal advice.